Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 14/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3149149 | 0.95 | CCR2 (0.64) | CCR2KCNH2ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3153224 | 0.89 | CCR2 (0.57) | CCR2KCNH2ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3153973 | 0.88 | CCR2 (0.57) | CCR2KCNH2ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3148173 | 0.88 | CCR2 (0.64) | CCR2KCNH2ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3050258 | 0.86 | CCR2 (0.64) | CCR2KCNH2ALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL3148931 | 0.86 | CCR2 (0.56) | CCR2KCNH2PTGDRPTGDR2 | |
| SCHEMBL3148934 | 0.86 | CCR2 (0.56) | CCR2KCNH2PTGDRPTGDR2 | |
| SCHEMBL3148167 | 0.86 | CCR2 (0.64) | CCR2KCNH2GAAF10 | |
| SCHEMBL3149811 | 0.86 | CCR2 (0.54) | CCR2KCNH2ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3052714 | 0.85 | CCR2 (0.63) | CCR2KCNH2ALDH1A1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | CCR2 417/4885KCNH2 80/4885ALDH1A1 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.